Page 218 - Drug Class Review
P. 218

Page 139 of 205
             Drug Effectiveness Review Project






























                                 placebo      97%   10%   14%   4%   5%                                placebo   26%   18%























                                 donepezil      96%   15%   15%   9%   9%   Post randomization exclusions: NR   Overall loss to follow-up: 46 (22.2%)  Loss to follow-up differential high: No   donepezil   18%   11%







                                                                     ITT: Yes


                                                           NR               Yes    Yes   Yes                           Fair















             Final Report Update 1     Authors:  Tariot et al.   Year: 2001   ADVERSE EVENTS:            Overall adverse effects reported:   Diarrhea   •   Vomiting   •   Nausea   •   Anorexia   •   Significant differences in adverse   events:      ANALYSIS:    ADEQUATE RANDOMIZATION:   ADEQUATE ALLOCATION   CONCEALMENT:  BLINDING OF OUTCOME   ASSESSORS:   ATTRITION (overall):     ATTRITION (treatment specific):   Loss to follow-up:   Withdrawals due to adverse events:        QUALITY RATING:      *primary outcome measures     Alzheimer's Drugs
   213   214   215   216   217   218   219   220   221   222   223